Clinical Trial Update: Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CRS-207 with pembrolizumab in previously treated malignant pleural mesothelioma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• CRS-207
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Aduro Biotech, Inc. | Conditions: Malignant Pleural Mesothelioma | Phase 2 | Status: TERMINATED | Results posted: 2019-02-19